124730-53-6

Basic information

• Product Name: ETHYL 2,3-DIHYDRO-1H-PYRROLO[3,2,1-IJ]QUINOLINE-6-CARBOXYLATE
• Synonyms: ETHYL 2,3-DIHYDRO-1H-PYRROLO[3,2,1-IJ]QUINOLINE-6-CARBOXYLATE;Ethyl 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylate;ETHYL 2,3-DIHYDRO-1H-PYRROLO[3,2,1-Lj]QUINOLINE-6-CARBOXYLATE
• CAS NO: 124730-53-6
• Molecular Formula: C₁₄H₁₅NO₂
• Molecular Weight: 229.27
• Mol File: 124730-53-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 398.4°C at 760 mmHg
• Flash Point: 194.8°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 1.48E-06mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ETHYL 2,3-DIHYDRO-1H-PYRROLO[3,2,1-IJ]QUINOLINE-6-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2,3-DIHYDRO-1H-PYRROLO[3,2,1-IJ]QUINOLINE-6-CARBOXYLATE(124730-53-6)
• EPA Substance Registry System: ETHYL 2,3-DIHYDRO-1H-PYRROLO[3,2,1-IJ]QUINOLINE-6-CARBOXYLATE(124730-53-6)

Safety Data

• Hazardous Substances Data: 124730-53-6(Hazardous Substances Data)

Usage

General Description

Ethyl 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinoline-6-carboxylate is a chemical compound with a complex molecular structure. It is an ester, containing an ethyl group and a carboxylic acid group. The compound belongs to the pyrroloquinoline class of chemicals and is used in organic synthesis and medicinal chemistry. Its unique molecular structure and properties make it a valuable compound for research and development in the pharmaceutical and chemical industries.

InChI:InChI=1/C14H15NO2/c1-2-17-14(16)12-9-15-8-4-6-10-5-3-7-11(12)13(10)15/h3,5,7,9H,2,4,6,8H2,1H3

Upstream product

• 152712-44-2 3-(3,4-dihydro-2H-quinolin-1-yl)-2-oxopropionic acid ethyl ester 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 70-23-5 ethyl Bromopyruvate 
• 14164-86-4 (3,4-dihydro-2H-quinolin-1-yl)-oxo-acetic acid ethyl ester 

Downstream Products

• 124730-56-9 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid 
• 5840-01-7 5,6-dihydro-4H-pyrrolo-[3,2,1-ij]quinoline 
• 905854-16-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(2-chloro-4-fluorophenyl)pyrrole-2,5-dione 
• 1000873-98-2 3(S),4(R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 tivatinib 
• 905854-03-7 (+)-3(S),4(S)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-j]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-02-6 Tivantinib 
• 1000873-98-2 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 345264-02-0 (5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)oxoacetic acid methyl ester 
• 345261-20-3 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dion 
• 1000873-98-2 (±)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 1000873-98-2 (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione 
• 905854-06-0 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(3-methoxyphenyl)pyrrole-2,5-dione 

Relevant articles and documents

Ir-catalyzed chemoselective reduction of β-amido esters: A versatile approach to β-enamino esters

The conversion of β-amido esters to β-enamino esters is an indispensable step for some synthetic approaches to alkaloids and related medicines. Known methods for such transformation are not only stepwise, but also proceed with low atom-efficiency. Herein, we report a direct and versatile approach that features the Ir-catalyzed chemoselective reduction of β-amido esters with 1,1,3,3-tetramethyldisiloxane (TMDS). In addition, a lack of some signals was observed in the 13C NMR spectra of some alicyclic β-enamino esters. This revealed a longstanding existing but being ignored phenomenon in the literature.

MELEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.